Mike Rigby

2.2k total citations
9 papers, 84 citations indexed

About

Mike Rigby is a scholar working on Molecular Biology, Radiology, Nuclear Medicine and Imaging and Immunology. According to data from OpenAlex, Mike Rigby has authored 9 papers receiving a total of 84 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 4 papers in Radiology, Nuclear Medicine and Imaging and 3 papers in Immunology. Recurrent topics in Mike Rigby's work include Monoclonal and Polyclonal Antibodies Research (4 papers), Toxin Mechanisms and Immunotoxins (3 papers) and Peptidase Inhibition and Analysis (2 papers). Mike Rigby is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (4 papers), Toxin Mechanisms and Immunotoxins (3 papers) and Peptidase Inhibition and Analysis (2 papers). Mike Rigby collaborates with scholars based in United Kingdom, United States and Switzerland. Mike Rigby's co-authors include Phil Jeffrey, Liuhong Chen, Amy Brown, Peter U. Park, Gemma Mudd, Paul Beswick, Katerine Van Rietschoten, Franz Hefti, Lisa Young and Neil R. Curtis and has published in prestigious journals such as Cancer Research, Journal of Medicinal Chemistry and Neuroreport.

In The Last Decade

Mike Rigby

6 papers receiving 82 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mike Rigby United Kingdom	5	54	32	24	15	11	9	84
S. Liu China	4	44 0.8×	47 1.5×	12 0.5×	22 1.5×	4 0.4×	13	107
Troy Bloom United States	3	33 0.6×	43 1.3×	13 0.5×	7 0.5×	2 0.2×	5	74
Verena Waller Switzerland	6	50 0.9×	27 0.8×	45 1.9×	2 0.1×	15 1.4×	7	90
Angeles Panadero United States	4	49 0.9×	39 1.2×	5 0.2×	6 0.4×	7 0.6×	4	87
Sarah Thurnheer Switzerland	3	69 1.3×	28 0.9×	28 1.2×	2 0.1×	6 0.5×	6	85
Marcel Buchholzer Germany	4	41 0.8×	21 0.7×	16 0.7×	5 0.3×	2 0.2×	7	69
Su‐Chen Huang United States	4	39 0.7×	31 1.0×	6 0.3×	3 0.2×	2 0.2×	4	81
Janice Schindler‐Horvat United States	5	28 0.5×	30 0.9×	21 0.9×		10 0.9×	6	71
Marisa Actis United States	5	99 1.8×	44 1.4×	2 0.1×	10 0.7×	9 0.8×	7	136

Countries citing papers authored by Mike Rigby

Since Specialization

Citations

This map shows the geographic impact of Mike Rigby's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mike Rigby with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mike Rigby more than expected).

Fields of papers citing papers by Mike Rigby

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mike Rigby. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mike Rigby. The network helps show where Mike Rigby may publish in the future.

Co-authorship network of co-authors of Mike Rigby

This figure shows the co-authorship network connecting the top 25 collaborators of Mike Rigby. A scholar is included among the top collaborators of Mike Rigby based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mike Rigby. Mike Rigby is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Zhang, Ying, et al.. (2025). The validation and clinical bioanalysis of the Bicycle® Toxin Conjugate zelenectide pevedotin in human plasma. Bioanalysis. 17(3). 177–185.

Walsh, Stephen J., Johanna Lahdenranta, Philip Huxley, et al.. (2024). Abstract 5807: Bicycle Toxin Conjugates®for the treatment of solid tumors. Cancer Research. 84(6_Supplement). 5807–5807.

Mudd, Gemma, Liuhong Chen, Katerine Van Rietschoten, et al.. (2022). Discovery of BT8009: A Nectin-4 Targeting Bicycle Toxin Conjugate for the Treatment of Cancer. Journal of Medicinal Chemistry. 65(21). 14337–14347. 58 indexed citations

Dickson, Amy L., Carly Campbell, Mike Rigby, et al.. (2021). Abstract 391: Molecular-based enrichment strategy for Nectin-4 targeted Bicycle toxin conjugate BT8009. Cancer Research. 81(13_Supplement). 391–391.

Rigby, Mike, Paul Beswick, Gemma Mudd, et al.. (2019). Abstract 4479: BT8009: A bicyclic peptide toxin conjugate targeting Nectin-4 (PVRL4) displays efficacy in preclinical tumor models. Cancer Research. 79(13_Supplement). 4479–4479. 6 indexed citations

Bacon, Chris M., Philip Sloan, Mike Rigby, et al.. (2019). Abstract A047: MT1-MMP Immunohistochemistry (IHC) analysis of tumor microarrays (TMAs) using a novel scoring system guides patient selection for BT1718 expansion cohorts. Molecular Cancer Therapeutics. 18(12_Supplement). A047–A047. 1 indexed citations

Bennett, Gavin, et al.. (2018). Abstract B135: The mechanism of action of BT1718, a novel small-molecule drug conjugate for the treatment of solid tumors expressing MT1-MMP. Molecular Cancer Therapeutics. 17(1_Supplement). B135–B135. 5 indexed citations

Harper, Sarah, Michael S. Saporito, Louise Hewson, et al.. (2000). CEP-1347 increases ChAT activity in culture and promotes cholinergic neurone survival following fimbria-fornix lesion. Neuroreport. 11(10). 2271–2276. 10 indexed citations

Newberry, Nigel R., Margaret S. Beer, Mike Rigby, et al.. (1992). L‐683,877: Pharmacological profile of a novel 5‐HT₃ receptor antagonist. Drug Development Research. 25(1). 17–28. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact